U0003 High‑Throughput SARS‑CoV‑2 NAAT Reimbursement

HCPCS Level II code U0003 covers high-throughput molecular testing for SARS-CoV-2 using amplified probe techniques to detect viral RNA. Introduced during the COVID-19 public health response, this code identifies laboratory-based nucleic acid amplification tests designed for automated, large-volume throughput. It matters nationally because these tests supported large-scale diagnostic capacity during pandemic response and continue to be relevant for surveillance, outbreak response, and clinical diagnosis where high-volume laboratory testing is required.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code's clinical purpose, the typical laboratory service setting, common billing considerations, and a summary of available payer coverage approaches. The publication also outlines what to expect in benchmarking and policy context related to high-throughput SARS-CoV-2 nucleic acid testing, and notes areas where specific payer policies or reimbursement details are not provided.

The content provides a concise reference for coding teams, laboratory billing managers, and policy analysts seeking a national-level summary of U0003, its clinical role, and the service environment where it is used. Data not available in the input is explicitly called out where applicable.

Billing Code Overview

HCPCS Level II code U0003 describes infectious agent detection by nucleic acid (DNA or RNA) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using amplified probe techniques with high-throughput technologies, as specified in CMS-2020-01-R. This code represents molecular diagnostic testing for SARS-CoV-2 that leverages automated, high-volume laboratory platforms to detect viral RNA.

Service type: Molecular diagnostic testing (nucleic acid amplification/probe technique) for SARS-CoV-2 using high-throughput platforms
Typical site of service: Clinical laboratories and high-throughput testing facilities (laboratory-based service line)

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical Context

A symptomatic adult presents to an outpatient drive-through testing site with fever, cough, and anosmia. A nasopharyngeal or anterior nasal swab is collected by a trained healthcare professional and sent to a high-throughput molecular laboratory for SARS‑CoV‑2 nucleic acid amplification testing using automated amplified probe techniques. The specimen undergoes accessioning, RNA extraction, amplification, and detection on high-volume platforms compliant with CMS guidance (CMS‑2020‑01‑R). Results are reported to the ordering clinician and public health authorities; positive results trigger isolation guidance and contact tracing workflows. Typical sites of service include outpatient laboratories, hospital reference laboratories, public health labs, and high-throughput commercial lab facilities that perform batch molecular testing.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	When reporting only the professional interpretation component (rare for automated high-throughput SARS‑CoV‑2 NAAT).
`TC`	Technical component	When billing only the laboratory technical component for the test run on automated equipment.

Taxonomy Code	Specialty	Notes
207Q00000X	Infectious Disease	Specialists who may order or interpret molecular SARS‑CoV‑2 testing.
208000000X	Pathology / Clinical Pathology	Laboratory directors and pathologists overseeing molecular testing quality and interpretation.
207L00000X	Pulmonary Disease	Clinicians frequently ordering SARS‑CoV‑2 NAAT for respiratory illness evaluation.
261QM0800X	Clinical Laboratory Science/Medical Laboratory Technologist	Personnel who perform and validate high‑throughput molecular assays.
363LF0000X	Public Health	Public health laboratory specialists managing large‑scale surveillance testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`U07.1`	COVID-19	Primary diagnosis for confirmed SARS‑CoV‑2 infection; direct indication for SARS‑CoV‑2 NAAT.
`J12.82`	Pneumonia due to coronavirus disease 2019	Used when COVID‑19 manifests as viral pneumonia and laboratory confirmation is required.
`R05`	Cough	Symptom prompting diagnostic testing for SARS‑CoV‑2.
`R50.9`	Fever, unspecified	Common presenting symptom leading to SARS‑CoV‑2 molecular testing.
`R43.8`	Other disturbances of smell and taste	Anosmia/ageusia frequently associated with SARS‑CoV‑2 infection and justification for testing.
`Z20.822`	Contact with and (suspected) exposure to COVID-19	Screening or surveillance testing following exposure.
`Z03.818`	Encounter for observation for suspected exposure to other biological agents ruled out	Used when testing performed to rule out COVID‑19 in an exposed or suspected individual.
`B97.29`	Other coronavirus as the cause of diseases classified elsewhere (historical use)	Occasionally used in legacy records to indicate coronavirus etiology when coding conventions require.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87635`	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) (Coronavirus disease [COVID‑19]), amplified probe technique	Directly analogous CPT code commonly used for individual SARS‑CoV‑2 NAAT reporting; may be billed alongside system-level laboratory administration codes.
`87471`	Infectious agent antigen detection by immunoassay technique, SARS‑CoV‑2 (Coronavirus disease [COVID‑19]), single step method; per specimen	May be performed in parallel in point‑of‑care antigen testing strategies, typically preceding or following NAAT for confirmation in some workflows.
`99000`	Handling and/or conveyance of specimen for transfer from the patient to a laboratory (Carrier)	Used when separate specimen transport or handling charges are billed associated with high‑volume testing logistics.
`G2023`	Infectious agent detection for SARS‑CoV‑2, specimen collection for current procedural terminology (CDC public health reporting)	Related to specimen collection and public health reporting processes that accompany laboratory NAAT testing.
`U0001`	CDC 2019 Novel Coronavirus (2019‑nCoV) Real‑time RT‑PCR Diagnostic Test Panel	Historically used in early pandemic reporting and may be present in payer mappings alongside high‑throughput U‑codes; relates as an alternative test code for molecular SARS‑CoV‑2 testing.

OpenPayer

Summary & Overview

HCPCS U0003: SARS-CoV-2 High-Throughput Nucleic Acid Amplified Test